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Abstract 33 
Wearable technology comprises miniaturized sensors (e.g. accelerometers) worn on the body 34 
and/or paired with mobile devices (e.g. smart phones) allowing continuous patient monitoring in 35 
unsupervised, habitual environments (termed free-living). Wearable technologies are revolutionising 36 
approaches to healthcare due to their utility, accessibility and affordability. They are positioned to 37 
transform Parkinson’s disease (PD) management through provision of individualised, comprehensive, 38 
and representative data. This is particularly relevant in PD where symptoms are often triggered by 39 
task and free-living environmental challenges that cannot be replicated with sufficient veracity 40 
elsewhere. This review concerns use of wearable technology in free-living environments for people 41 
with PD. It outlines the potential advantages of wearable technologies and evidence for these to 42 
accurately detect and measure clinically relevant features including motor symptoms, falls risk, 43 
freezing of gait, gait, functional mobility and physical activity. Technological limitations and 44 
challenges are highlighted and advances concerning broader aspects are discussed. Recommendations 45 
to overcome key challenges are made. To date there is no fully validated system to monitor clinical 46 
features or activities in free living environments. Robust accuracy and validity metrics for some 47 
features have been reported, and wearable technology may be used in these cases with a degree of 48 
confidence. Utility and acceptability appears reasonable, although testing has largely been informal. 49 
Key recommendations include adopting a multi-disciplinary approach for standardising definitions, 50 
protocols and outcomes. Robust validation of developed algorithms and sensor-based metrics is 51 
required along with testing of utility. These advances are required before widespread clinical adoption 52 
of wearable technology can be realised.  53 
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Introduction  54 
Wearable technology and connected devices (WTCD) are positioned to become ubiquitous in 55 
research and healthcare settings. WTCD comprise electronic technology worn on the body or 56 
embedded into mobile phones, watches, bracelets, and clothing, amongst others. The generic appeal 57 
of WTCD is obvious. Patient monitoring is free from contextual or environment barriers making 58 
assessment at home and in the community over continuous time periods (termed free-living) feasible 59 
and ecologically valid 1. Moreover data are free from the confounds of observer bias and attentional 60 
compensation associated with a one off testing session under observation 2, while devices are 61 
relatively low cost making their use economically as well as practically feasible. 62 
The benefits of remote monitoring with WTCD are multi-fold. Clinically, continuous 63 
monitoring of symptom severity and therapeutic response provides nuanced assessment. A complete 64 
picture of disease burden is available both to the clinician and the patient incorporating a broad range 65 
of features from the ‘micro’ level of detail (e.g. disease symptoms, medication response and 66 
fluctuations, gait characteristics, turning, frequency of falls) through to more ‘macro’ levels (e.g. 67 
habitual patterns of walking/activity, inactivity and sleep) (Figure 1). Enriched measurement, coupled 68 
with ease of use, also has implications for industry, paving the way for identification of early disease 69 
with the potential for enhanced diagnostic and progression markers (fundamental for trials of novel 70 
therapeutics and disease modifying therapies), harmonisation of outcomes and standardized testing 71 
protocols to enhance recruitment and assessment of treatments in clinical trials. For the patient, 72 
WTCD offer insight into symptoms, therapeutic efficacy and habitual mobility in the context of 73 
everyday life contributing to enhanced self-management that is both bespoke and contextualised. 74 
Despite the recent explosion of low cost commercially available devices (for the general 75 
population) promoting personal monitoring and feedback, the application of WTCD in healthcare has 76 
not yet been established 3. The lure of utility (i.e. ease of use, broad application, and low cost) is 77 
strong; however standards for clinical adoption and research application are far higher. While 78 
technology and design have advanced, algorithm development and data analysis have not kept pace. 79 
Validity and reliability are paramount and inform accurate detection and monitoring of disease and 80 
this next step is critical before widespread adoption 4. Although there are promising signs, there is still 81 
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no single system/gold standard being used for remote monitoring 5, 6. Therein lies both the opportunity 82 
and the challenge. 83 
This paper considers issues related to free-living monitoring from predominantly single 84 
sensor-based devices (e.g. accelerometers and gyroscopes). We examine the ability of WCTD 85 
algorithms to accurately detect a range of clinical features and report on criterion and discriminative 86 
validity of outcomes derived from WCTD. Utility and feasibility are also considered. Clinical features 87 
include monitoring of motor symptoms, medication response, sleep, falls and falls risk, freezing of 88 
gait (FOG), gait, functional mobility and physical activity (ambulatory activity and sedentary 89 
behaviour).  This rapidly expanding field and has been the subject of a number of recent systematic 90 
reviews 7-9 including Sánchez-Ferro et al. within this issue to which the reader is referred. We have 91 
therefore adopted a broader approach and provide a structured overview of the current status of 92 
continuous patient monitoring in the home and community in Parkinson’s disease (PD) which we 93 
define as ‘free-living’. We address four key aims: (1) the role and benefits of free-living monitoring; 94 
(2) the validity and utility (acceptability and feasibility) of WTCD to monitor a range of key clinical 95 
features relevant to PD; (3) critical challenges for adoption of WTCD for free-living assessment; and 96 
(4) future developments in this rapidly developing field. Throughout we focus mainly on the 97 
application of passive (no interaction from patient) single sensor-based devices and their application 98 
in PD but where relevant draw from work in ageing cohorts. Finally, we make recommendations 99 
based on this overview to progress free-living monitoring in PD. 100 
 101 
Does free-living monitoring confer an advantage over clinical assessment in PD?  102 
Due to its heterogeneity and complexity, clinical assessment of PD is challenging. The 103 
intrinsic, fluctuating nature of PD and biphasic medication response in advanced disease requires 104 
continuous evaluation over prolonged periods to gain an accurate picture of symptoms and their 105 
fluctuations. The influence of attention on performance is well recognised especially with symptoms 106 
such as FOG, leading to an inaccurate clinical picture 2, 8. Assessments requiring concentration and 107 
recall such as falls diaries are further compromised by cognitive impairment, thus limiting utility. 108 
Also, use of clinical scales is restrictive. The Unified Parkinson’s Disease Rating Scale, (UPDRS) 10, 109 
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although highly relevant to PD, is dependent on the patient’s status at the time of assessment and 110 
limited by subjectivity and clinical expertise. WTCD overcome many of these limitations by 111 
objectively quantifying clinically relevant outcomes. Variation in testing is reduced 3, 11, 12. Patients 112 
also have much to gain from this approach, with less emphasis during clinical visits on symptom 113 
recall and evaluation of therapeutic response. Continuous monitoring also provides greater potential 114 
for patient involvement in defining optimal management 12.   115 
Measurement with WTCD is diverse. A single WTCD has the potential to provide the 116 
clinician/researcher with a comprehensive picture of their patient within one assessment. For example, 117 
Figure 1 shows that placement of a single sensor can quantify features such as volume and pattern of 118 
habitual behaviours (e.g. walking, sleeping, sedentary time, Figure 1, A) (defined here as macro). The 119 
raw signal (Figure 1, B) can then be further broken down to detect very discrete features (e.g. a fall, 120 
gait characteristics, turning and freezing, figure 1, C-H) (defined here as micro). Taking this approach 121 
enables multi-level measurement 13.   122 
<Figure 1> 123 
 124 
Free-living assessment of clinically relevant features in PD: a valid alternative to conventional 125 
clinical assessment? 126 
Despite the obvious advantages of free-living assessment an important question remains – are 127 
the outcome measures derived from WTCD suitable for current clinical use and will patients and 128 
professionals use WTCD? Table 1, which form the basis of this section, provides an overview of 129 
detection accuracy, validity and utility of some WTCD. Our main inclusion criterion was that WTCD 130 
had been applied to free-living monitoring under either totally unsupervised or scripted protocol 131 
conditions, with an exception made for studies where tests are conducted in formal settings to 132 
optimise validation, such as detection of FOG. We report criterion validity from studies that examine 133 
the association between WTCD-derived outcomes and other measures such as clinical scales. We also 134 
report studies that test discriminative validity, which we define as the ability of WTCD-derived 135 
outcomes to discern groups or phenotypes. The list is by no means exhaustive but provides a current 136 
overview and highlights the vast interest in the area. We do not review static postural control despite 137 
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its obvious relevance to PD 14, 15, because studies are laboratory and/or clinic based, however, facets of 138 
postural control (e.g. dynamic, turning) are considered.  139 
 140 
Motor symptoms, medication response and sleep.  Continuous monitoring has a lot to offer over 141 
snapshot clinical assessments which may not reveal the true extent of symptom burden. Earlier use of 142 
WTCD for motor symptom measurement focused on evaluation of a single symptom to detect 143 
hypokinesia, dyskinesia, tremor, bradykinesia, and akinesia derived on/off medication status 16, 17. 144 
This has evolved to assessment of multiple motor symptoms using either a single 18-20 or multiple 145 
sensor systems 17, 21-24.  To date preliminary results are promising. Overall, motor symptom 146 
measurement using WTCD is accurate and comparable with more established methods with some 147 
aspects of validity tested. Criterion validity is established for most motor symptoms (tremor, 148 
bradykinesia, dyskinesia) showing moderate to high correlations overall (R > 0.65) with standard 149 
clinical scales (e.g. UPDRS, Abnormal Involuntary Movement Score (AIMS), Modified Bradykinesia 150 
Rating Scale (MBRS), etc.) (see Table 1 for references). Measures of bradykinesia also show high 151 
specificity (88%) and sensitivity (95%) when compared to standardised tests (e.g. the Dot Slide test) 152 
18. Studies that test discriminative validity are not as advanced, apart from the work by Horne et al. 153 
which discerns motor symptom fluctuations in early stages of PD 20. Single sensors are sufficiently 154 
robust for application, although there are question marks over aspects of utility for some systems 155 
which require technical mastery and are demanding on the user (see ‘Utility’ section). Whilst there 156 
have been a number of key developments in this area with motor symptom monitoring assessed at 157 
home, the test protocols are still largely controlled and scripted as highlighted in table 1. True passive 158 
monitoring without patient input is as yet an area to be developed but remains the area of greatest 159 
interest as it will give the most ecologically valid picture of motor symptom burden and therapeutic 160 
efficacy. Assessment of sleep also shows promise. WTCD-derived outcomes for sleep discriminate 161 
PD from older adults (OA) 25, 26 for macro outcomes (e.g. number and size of movements) with people 162 
with PD also showing increased episodes of nocturia, fewer turns during sleep, and greater arm 163 
movements. 164 
 165 
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Falls and falls risk. Accurate detection of falls and falls risk (ideally before the first ever fall) would 166 
greatly inform clinical management and therapeutic development and WTCD has a role to play. Real-167 
world detection of falls however is technically challenging. A plethora of algorithms, devices, and 168 
device locations (chest, waist or wrist 27-31) have been tested to improve the accuracy of falls 169 
detection, however, studies are almost completely limited to controlled settings and conducted on 170 
young healthy adults. Kangas et al. provides a rare example of using WTCD for falls detection in the 171 
real-world where falls were measured in institutionalised OA and verified by an observer 32. Fall 172 
detection sensitivity was 80% with a falls alarm rate per hour of 0.025, denoting one false alarm over 173 
40 hours of recording. This points to high accuracy, although the testing environment was far 174 
removed from ‘free-living’, and generalisability is therefore weak. Application in PD remains an area 175 
of unmet need. An alternative approach is to predict falls risk using WTCD which, in contrast to falls 176 
detection, is a more advanced field for both older adults and PD. Moreover, addressing a falls 177 
prevention approach could be argued to have greater clinical relevance 33, 34. Studies have compared 178 
groups with and without falls in PD using free-living monitoring over 3-7 days. Falls risk factors 179 
derived from gait during free-living walking bouts 33, 34 were superior to laboratory-based gait speed 180 
and fall history to discriminate fallers from non-fallers 35-38. Discriminative validity has been 181 
established for both macro and micro characteristics of gait and sedentary behaviour (Figure 1, A-B) 182 
which are associated with type of PD fallers 39 and fall history (fallers vs. non-fallers) in OA 38, 40 and 183 
PD 41, respectively. Micro features may offer more than macro features 36, 37, and contribute 184 
substantially to predicting falls both in fallers and non-fallers 37, 38. Further refinement of algorithm 185 
and system development is however required to take the field forward. 186 
 187 
Freezing of gait. Gait disturbances such as FOG are notoriously difficult to replicate in a controlled 188 
environment because of its spontaneous nature and the non-specific and poorly understood triggers 189 
that provoke it 3. Clinical scales such as the UPDRS and NFOG 42 are subjective and therefore 190 
limited. Despite the obvious need, free-living monitoring of FOG in PD has not been achieved. 191 
Detection of FOG episodes has been tested in controlled and structured conditions where FOG is 192 
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provoked during the ‘off’ condition, using either timed-up-and-go (TUG) 43 or walking tasks. 44 193 
Studies show high sensitivity (range: 84.3%-86.2%) and moderate to high specificity (range 66.7%-194 
98.74%) for detection of FOG, and moderate agreement with clinical measures 43, 44. These results 195 
provide a critical step from which validation can be extended to free-living. An alternative approach is 196 
to identify potential predictors of FOG to understand the mechanisms and target therapeutic 197 
developments. A recent study comparing freezers vs. non-freezers found frequency-based gait 198 
characteristics collected during 3 days of free-living discriminated freezers. Gait characteristics were 199 
also moderately correlated with clinical measures of FOG 45. Further work is needed before free-200 
living monitoring can be used for FOG detection or indeed for understanding the characteristics of 201 
FOG but initial results are promising. 202 
 203 
Gait. Measurement of gait per se (micro characteristics - Figure 1, E-F) is also of interest to the 204 
clinician to evaluate efficacy of clinical management (due to dopa-resistance) as well as for its 205 
potential for use of discrete gait characteristics as diagnostic, prognostic and progression markers 46-48. 206 
Gait assessment during free-living assessment also captures ongoing environmental and cognitive 207 
challenges which impair gait performance. Assessment in this context has greater ecological validity 208 
and gives a true picture of the burden of disease 3, 7, 49. Algorithms have been validated to detect 209 
discrete gait characteristics in the laboratory and also in proxy validation studies 50-55. Results showed 210 
good agreement with trusted gold standard reference (e.g. GaitRite or optical motion capture systems) 211 
for the majority of gait characteristics with potential advantages for asymmetry and variability 212 
measures. Apart from Del Din et al. 49, the few studies that have examined gait in free living 213 
conditions, quantify few gait characteristics 56-61. Discriminative validity has been tested, and has been 214 
shown to discriminate between PD and OA 49, 57, phenotypes of PD 61 and PD with higher or lower 215 
cognitive functions 60. Aside from studies exploring falls and FOG risk highlighted previously 57 only 216 
one study has investigated the effect of environment on gait. Free-living gait characteristics showed 217 
better discriminative validity than those collected in the laboratory, especially for medium to long 218 
bouts 49. Although initial work is promising, future work is required to confidently realise continuous 219 
monitoring of gait. There are also some fundamental challenges to the field (outlined below). 220 
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 221 
Measures of functional mobility.  Tests of functional mobility such as turning and Timed up and Go 222 
(TUG) 62-64 measure combined movements that invariably incorporate postural transitions. Detection 223 
of movements during functional mobility tasks appears accurate 62, 63, 65, and validity (criterion and 224 
discriminative) has been established by a limited number of studies 62, 65. Mean turn velocity, slower 225 
walking and turning, shorter steps and lower cadence distinguished PD from controls 62, 64 and also 226 
showed greater sensitivity to dysfunction than clinical rating scales 64, 65. Of interest, free-living 227 
assessment appears to discriminate pathology better than testing in the laboratory 54 (Figure 1, G). 228 
Measurement of functional mobility tasks can therefore be undertaken with a degree of confidence 229 
during a standardised test at home, although further work is required to replicate these findings. 230 
 231 
Ambulatory activity and sedentary behaviour.  One of the earliest applications of WTCD aimed to 232 
quantify physical activity (e.g. ambulatory activity) amid rising concerns of the negative effects of 233 
sedentary behaviour on well-being. This is particularly relevant for people with PD because of the 234 
beneficial health benefits activity confers, and its role in mitigating secondary deficit. Ambulatory 235 
activity provides a picture of the true burden of disease and therapeutic efficacy 66. Proxy measures 236 
such as activity logs and diaries are unreliable and lack responsiveness compared with continuous 237 
WTCD monitoring 67. Physical activity such as intensity of movement (energy expenditure), temporal 238 
periods (bouts) of ambulatory activity (e.g. bouts of walking) and sedentary behaviours are quantified, 239 
from which macro outcomes can be derived 66, 68-70 (Figure 1, A-B). The field has advanced further 240 
with the application of non-linear approaches to data analysis which in some instances are more 241 
sensitive than measures of central tendency (Table 1, Figure 2), such as pattern (alpha (α)) rather than 242 
volume of sedentary behaviour showing discriminative properties 71. Ambulatory activity 243 
differentiates disease stage 66, and progression 72, 73 and shows increased sensitivity to intervention 68, 244 
74. Rochester et al. 68 demonstrated the advantages of WTCD versus clinical measures when 245 
examining the impact of deep brain stimulation (DBS) on ambulatory activity. Whilst standard 246 
clinical measure for gait speed (4 meter test), levels of activity (Nottingham extended activities of 247 
daily living index (NEADL)) and disease progression (Hoehn and Yahr) failed to show the positive 248 
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effects of DBS on the outcomes, WTCD-based measures demonstrated significantly improved 249 
patterns of daily activity. Use of WTCD to measure ambulatory activity and sedentary behaviour is 250 
the most advanced of all the fields discussed in this section, and the most widely adopted. Nonetheless 251 
there are still questions over its application, driven by lack of common definitions of ambulatory 252 
activity, validation procedures and structured protocols in controlled settings for validation of 253 
algorithms 6. These will be considered below. 254 
 255 
Utility and feasibility of WTCD: how acceptable are they? Most studies do not intentionally test the 256 
feasibility and utility of WTCD but instead draw on secondary data such as informal comments from 257 
patients, reporting adverse events, data loss, or attrition in sensor use over the study period. 258 
Importantly, there are no overwhelmingly negative reports, suggesting that WTCD are broadly 259 
accepted. Although few studies have intentionally tested utility (which we describe as ‘formal testing’ 260 
in Table 1), some focused efforts have been made. Utility has been tested for wearable systems 261 
comprising interactive 75 or multiple sensors 17, 22, 23, 76, using both non-standardised and standardised 262 
questionnaires and rating scales23 (e.g.  the post-study usability questionnaire), comfort 75, 76 (e.g. 263 
comfort rating scale (CRS)) and ‘wearability’/exertion 76 (e.g. Borg CR-10 Scale, Rapid Entire Body 264 
Assessment (REBA)). Overall the response has been positive, with WTCD generally well tolerated, 265 
comfortable and easy to use. Compliance is high, although in some cases results were influenced by 266 
socio-cultural aspects which may have positively biased results 23.  267 
 268 
In summary, to date there is no fully validated WTCD system for continuous monitoring of patient 269 
clinical features. Overall, studies are small, there is no consistent reporting of outcome measures, 270 
protocols differ, and devices differ along with device placement. Comparison to a gold standard is 271 
difficult. Knowledge on patient acceptability is limited. A clear process for validation including 272 
replication in external data sets is essential with appropriate reporting according to a standard. 273 
However the WTDC community is aware that this is an important and emerging area of research with 274 
potential for high clinical uptake, and collaborative efforts are underway to redress these issues (see 275 
reviews 7-9). Challenges to implementation are due at least in part to broader technological and 276 
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practical concerns which are common to all WTCD and influence their state of readiness, irrespective 277 
of application and use. Until these fundamental issues are redressed, robust use of WTCD will be 278 
compromised. The next section highlights some of these broad concerns and discusses approaches to 279 
advance the field. 280 
 281 
Challenges to clinical adoption   282 
We address 3 key areas fundamental to the use of WTCD that apply to all areas of 283 
measurement: (i) clear definitions of the clinical feature of interest, (ii) validation of real-world data 284 
and WTCD technical challenges, and (iii) consensus on outcomes. We illustrate these using examples 285 
from our own experience in gait and activity and that of others (Figure 3). Finally we summarise 286 
challenges with recommendations for future work and practical suggestions to inform the interested 287 
user (Table 2).   288 
 289 
Defining the clinical feature. Although on the face of it this seems simple, there are many examples 290 
where unclear definitions have led to inconsistencies in outcomes and confusion when comparing 291 
between studies. A good example relates to ambulatory activity, from which macro (e.g. walking 292 
bouts) and micro level gait outcomes are derived that underpin many different clinical and research 293 
questions (Figure 1). This stems from a basic definition of what constitutes a walking bout. In some 294 
studies only purposeful bouts of walking are considered (with a cut-off threshold > 60 seconds) 295 
because regular steady state is more likely to be achieved, thus avoiding potential errors in 296 
misclassification from short bouts. However this is problematic because adults perform almost 90% of 297 
walking bouts in less than 60s 40, 49, 77 resulting in significant data loss and potentially missing the 298 
most relevant data (such as change in variability of walking pattern). Another approach is to include 299 
all bouts of walking 49 which is arguably more relevant in patient populations. However this is not a 300 
complete solution because disagreement also exists regarding the number of steps required for a bout, 301 
which may vary, ranging from >3 steps to >10 steps. As a consequence comparison across studies is 302 
impossible where difference in step counts range from 2,000 to 10,000 steps 66, 68, 72, 73. The situation is 303 
further complicated by the use of ‘ghost’ (unknown to the end user and hard-wired into WTCD) 304 
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thresholds used by the manufacturer to define consecutive bouts of walking  that have a major impact 305 
on macro outcomes 78 (e.g. total number and pattern of walking bouts) (Figure 3, (1)). This uneven 306 
approach significantly impacts on both macro and micro outcomes and therefore consensus as to a 307 
clear definition of walking is urgently required 6, 78. Attempts are underway to improve definitions 308 
which will greatly help (Chastin et al.: AlPHABET: Development of A Physical Behaviour 309 
Taxonomy with an international open consensus1).  310 
 311 
Algorithm development, validation and technical challenges: Influence of context and protocol. 312 
Establishing a gold standard to test algorithm validity for the range of features highlighted in this 313 
review during continuous uncontrolled monitoring in a free-living environment is a major challenge 314 
without obvious solutions. Real-life is unpredictable and unstructured. For example, context 315 
(environment and task) affects walking speed and direction which has implications for accuracy of 316 
algorithms used to detect steps and phases of the gait cycle from which gait characteristics are 317 
determined (Figure 3). Studies often adopt a number of different testing protocols and various sensor 318 
configurations (type and location (upper or lower body, Table 1) which also impacts the signal 319 
waveform influencing the accuracy of the algorithm used to extract micro outcomes and other type of 320 
information (features, outcomes). Moreover algorithms are usually validated using healthy controls 321 
data and adopted for analysing other groups’ data (i.e. PD) without considering that speed (fast or 322 
slow), pathology itself and disease stage may impact on the raw signal (Figure 3, (2)) and therefore 323 
influence algorithm performance. In addition other technical considerations need to be taken into 324 
account. Many commercial devices adopt black box designs with un-validated firmware/software 79 325 
which account for at least some of the significant disagreements in reported results 80, 81.  Other 326 
uncertainties due to externally induced motion (e.g. cars, lifts) also impact on accuracy to detect 327 
features of interest 81. Static and dynamic re-calibration of WTCD to account for possible axis 328 
misalignment or sensor alterations due to damage (device dropped, contact with water etc.) is also 329 
advised 82, however rarely undertaken because procedures are complicated and expensive. Further 330 
sources of variability are also introduced through changes in external factors such as weather, mood 331 
                                                 
1 https://osf.io/2wuv9/ 
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or medication, influencing analysis of the signal. Collectively these result in errors and decreased 332 
confidence in outcomes and conformity to everyday use. Algorithm development will ultimately 333 
refine extraction and a joint approach such as use of secondary data sources will aid interpretation, for 334 
example data from patients’ diaries, testimony from carers, and use of clinical records 83. All of these 335 
potential sources of error should be considered and some suggestions are provided in Table 2. 336 
 337 
Determining optimal outcome measures. Table 1 shows the vast range of outcomes reported. 338 
Standardised measurement is urgently needed with a clear rationale for selection of outcomes from 339 
which clinimetric testing will allow a refined battery of measures to emerge to encourage 340 
harmonisation across studies. Examples of measurement frameworks have been described 46, 49 341 
including our own micro and macro level structure used throughout this paper 47. Others 37, 38, 45, 57, 61 342 
beside volume outcomes (e.g. total number of walking bouts, etc.) defined as ‘quantity’ metrics, use 343 
novel frequency-based outcomes to characterise gait (a) symmetry, variability and stability (e.g. 344 
harmonic ratio, amplitude of dominant frequency, dynamic stability, etc.) defined broadly as ‘quality’ 345 
metrics. These novel quality measures, although very promising for discriminative validity, may be 346 
difficult to interpret in clinical practice. 347 
 348 
<Figure 2> 349 
<Figure 3> 350 
 351 
Free-living monitoring in PD: where to next? 352 
Modern devices incorporate a range of inertial sensors such as accelerometers, gyroscopes, 353 
magnetometers with Bluetooth connectivity which constitute cutting edge WTCD. While use is 354 
currently limited to controlled settings, improvements in battery technology will improve the accuracy 355 
of measurement addressing some of the challenges highlighted earlier. Moreover, novel methods for 356 
advanced data processing are being developed to reduce computational load with advanced 357 
computational processing carried out remotely via smartphone or in the cloud extending the 358 
application of WTCD 84. Studies have also investigated the use of smart phones (and audio devices) 359 
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which regularly come with the necessary hardware to quantify symptoms, movement or gait 85. These 360 
devices capture, analyse and relay information via cellular or other wireless networks and also provide 361 
a more comprehensive assessment such as the addition of a microphone for use with speech analysis 362 
algorithms in PD diagnosis 86, 87 and visual displays to facilitate applications (apps) for the study of 363 
cognition 88.  Rigorous device testing however is needed to ensure confidence in their application.  364 
Long term monitoring via a smart phone facilitates network interconnectivity and integration 365 
to the Internet of Things (IoT) 5,  through delayed or real-time uploading of data to cloud computing 366 
infrastructures. Data can be relayed to the patient (bio-feedback) via unobtrusive displays, haptic and 367 
audible cues. Data is stored and sent to clinicians for tracking disease progression, optimising disease 368 
management and providing further, more clinically informed feedback to the patient. Data storage and 369 
data access on this scale constitutes ‘big data analytics’. Developments in this field can expand 370 
assessment to capture the ‘lived experience’ or ‘lifespace’ of PD, capturing the extent to which people 371 
travel and their patterns of movement within the community 89. This is exemplified by a recent 372 
collaborative project between the Michael .J Fox Foundation and Apple utilising their projects, 373 
FoxInsight2 and the Apple ResearchKit3 (inc. the Parkinson mPower app4 available via iTunes), 374 
respectively. 375 
Collection of data on the scale and in a free-living context raises new ethical challenges with 376 
respect to acquisition, analysis and storage.  Current ethical reviews may not be sufficient to identify 377 
modern issues 90. Technology and terminology has evolved faster than legal and ethical systems and 378 
unforeseen issues can emerge 91. Informed, principled, and collaborative experimentation are therefore 379 
necessary to ensure privacy and confidentiality, and compliance with ethical principles. 380 
 381 
Conclusions and recommendations  382 
There is no doubting the possibilities and potential of real world monitoring and assessment 383 
of clinical features for people with PD. It is conceivable to imagine a future where micro level data is 384 
used to enhance diagnostics, measure efficacy of intervention and monitor disease progression, and 385 
                                                 
2 The Michael J. Fox Foundation for Parkinson's Research, https://foxinsight.michaeljfox.org/ 
3 Apple Inc., http://www.apple.com/uk/researchkit/ 
4 http://parkinsonmpower.org/ 
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predict risk of disease, falls and cognitive decline. Macro level data, on the other hand, reflects the 386 
global burden of disease and impact of therapy. Both sources of data provide insights into 387 
personalised treatment. As this special issue in the journal indicates, this is a rapidly developing field. 388 
However, much work remains before widespread clinical adoption is a reality. We highlight key 389 
recommendations and some practical solutions to move this field forward (Table 2).  These challenges 390 
are likely to be met most effectively by adopting a multidisciplinary approach between key 391 
stakeholders such as clinicians, patients, engineers, computer scientists, and statisticians. 392 
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Tables 
Table 1: Studies examining free-living monitoring of Parkinson’s disease (PD) using wearable technology and connected devices (WTCD).  
Number and position of WTDC used in each study is detailed in column two using a colour code (blue = chest, violet = wrist, black = pocket, green = thigh, 
yellow = shank, orange = ankle, grey = foot, red = lower back). 
† Clinical feature/ activity detected or measures has been classified using three types of validity: 1) accurate detection of clinical feature/ method of appraisal: 
the ability of WCTD algorithms to accurately detect a clinical feature/activity which is comparable to detection by another means - in the study cited or 
previous studies (e.g. self-report, EMG); 2) criterion validity: the association between WTCD-derived outcomes and measures such as clinical scales; and 3) 
discriminative validity: the ability of WTCD-derived outcomes to discriminative between groups. Formal testing of utility (feasibility/compliance 
intentionally tested and reported) of WTCD is also reported. 
 
 
Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
Motor symptoms and medication response 
Das et al. 
(2012), 2 PD, 
4*21 
Accelerometers --█-- 
█ █ █ █  
Dyskinesia, 
tremor 
Yes, against patients’ 
diaries using weakly 
supervised machine 
learning technique. 
Acceleration derived features 
(Mean energy, high frequency 
energy content, correlation, 
frequency domain entropy) 
No No No 
Griffiths et al. 
(2012), 34 
PD/10 OA, 1018 
Parkinson's 
KinetiGraph (PKG; 
Global Kinetics 
Corporation) █ 
Bradykinesia, 
dyskinesia 
Yes, for bradykinesia 
against dot slide task 
measure (specificity 
88%, sensitivity 95%) 
during scripted tests.  
Acceleration derived features: 
Mean Spectral Power within 
specific bands, peak,  
amount of time with no 
movement 
Yes, dyskinesia against the 
AIMS score and both 
dyskinesia and bradykinesia 
against UPDRS III and IV 
No No 
Mera et al. 
(2012), 10 PD/ 
10 OA, 3-619 
Kinesia™ █-- 
Motor tasks, 
tremor, 
bradykinesia, 
motor 
fluctuations 
No 
Symptoms severity scale (0-4 
points), voluntary movement 
threshold  evaluated with 
gyroscope derived features 
(RMS, peak of power 
spectrum) 
Yes, for tremor and 
bradykinesia. Potential 
issues of recognition when 
the 2 symptoms overlap. 
Yes against videos in the 
lab for symptom severity 
scale validated against 
UPDRS tremor and MBRS 
speed, amplitude and 
rhythm scores in previous 
work 75, 92 
No 
Yes, formal 
testing 
previous work 
75 
Pastorino et al. 
(2013), 2 PD, 7 
ALA-6g (PERFORM) 
--█-- █ █ █ █ 
Akinesia, 
ON/OFF state 
Yes, ‘proof of 
concept’ validation 
Level of akinesia No No 
Yes, formal 
testing 
18 
 
Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
(but 32 hours 
analysed) 17   
against patients’ 
diaries 
Tzallas et al. 
(2014), 12 PD, 
5 (8 hours per 
day)22 
ALA-6g (PERFORM) 
--█-- █ █ █ █ 
Tremor, LID, 
Bradykinesia, 
FOG 
Yes, in the lab and 
during structured test 
(e.g. for FOG events 
Opening door/ 
Straight 10m walking) 
against video 
annotations. 
Acceleration derived 
measures (time and frequency 
domains, RMS, range, 
entropy, energy) 
Yes, machine learning and 
leave one out validation 
technique validated in the 
lab and applied in free-
living conditions and 
compared against patients’ 
diaries.  Use of videos in 
the lab for assessing 
symptoms severity using 
UPDRS.  
No 
Yes, formal 
testing 
Ferreira et al. 
(2015), 11 PD, 
12 weeks 23 
SENSE-PARK System 
█ █ █  
Gait, 
hypokinesia, 
dyskinesia, 
tremor, sleep 
No/NA (feasibility 
study and usability) 
NA NA No 
Yes, formal 
testing 
Hammerla et al. 
(2015), 34 PD, 
724 
Axivity AX3 █ █ 
Sleeping, 
ON/OFF state, 
dyskinesia 
Yes, in the lab 
(against video 
recordings) using 
machine learning and 
leave one out 
validation technique, 
in free-living 
conditions results are 
compared against 
patients’ diaries. 
Model pre-trained in 
free-living conditions 
did not give good 
results (laboratory 
data is a poor model 
for naturalistic 
behaviours)  
Acceleration derived 
measures (magnitude, jerk, 
power spectral density, etc.) 
No No 
Yes, formal 
testing but in 
subsequent 
work 93 
Horne et al. 
(2015), 64 
PD/38 OA, 1020 
Parkinson's 
KinetiGraph (PKG; 
Global Kinetics 
Corporation) █ 
Bradykinesia, 
dyskinesia, 
fluctuations 
Yes, against measures 
of bradykinesia and 
dyskinesia (previous 
work see Griffiths 
2012) 
Fluctuation Score based on 
Interquartile Range of 
bradykinesia and dyskinesia 
scores. 
Yes, against clinical scores 
derived measure 
Yes No 
19 
 
Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
Sleep 
Prudon et al. 
(2013), 106 
PD/99 OA, 3 
nights94 
Acti-watch, Camntech 
█ █ 
Leg 
movements 
during sleep 
Yes, in patients with 
periodic leg 
movement (against 
electromyography), 
previous work 
Periodic leg movements index 
Yes, against disease 
severity 
No No 
Louter et al. 
(2015), 11 PD, 
2 nights25 
Dynaport McRoberts █ 
Turning 
during sleep 
Yes, against 
polysomnography in 
adults with obstructive 
sleep apnoea 
syndrome, previous 
work 95 
Acceleration derived 
measures (e.g. mean) and 
axial movement measures 
(frequency, size, duration, 
speed) 
Yes, against Acti-watch but 
in young healthy adults 
previous work 95 
Yes 
Yes, no 
formal testing, 
previous work 
Sringean et al. 
(2015), 19 PD, 
1 night26 
NIGHT-Recorder 
system █ █ █ █ █ 
Turning, 
Standing 
No, video and sleep 
diaries collected but 
validity not formally 
tested. 
Acceleration and gyroscope 
derived measures (duration of 
sleep, axial movements, 
velocity, etc.) 
Yes, against clinical scores 
(UPDRS axial score, item 
#28, etc.) 
Yes 
Yes, no 
formal testing, 
no adverse 
events 
reported 
Falls and Falls Risk 
Weiss et al. 
(2013), 71 OA, 
335 
Dynaport McRoberts █ 
Walking (at 
least 60s) 
No 
Number of walking bouts, 
walking duration, total 
number of steps, median 
number of steps per bout, 
bout duration, cadence, step 
and stride regularity, 
frequency domain measures 
(harmonic ratio, amplitude, 
slope and width of dominant 
frequency), step duration, step 
symmetry, acceleration range, 
etc.  
Yes, against clinical scores 
of fall risk and laboratory 
based measures 
Yes No 
Weiss et al. 
(2014), 107 PD, 
336 
Dynaport McRoberts █ 
Walking (at 
least 60s) 
No 
Number of walking bouts, % 
of activity duration, total 
number of steps, median 
number of steps per bout, 
bout duration, cadence, stride 
regularity, frequency domain 
measures (harmonic ratio, 
Yes, against clinical scores 
of fall risk 
Yes 
Yes, no 
formal testing, 
data loss 
reported. 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
amplitude and width of 
dominant frequency), etc. 
Brodie et al. 
(2015), 18 EF, 
58 (average)40 
Senior Mobility 
Monitor (SMM, 
Philips) --█-- 
Walking (at 
least 3 or 8 
steps) 
No 
Steps per day, walking bouts 
per day, steps per bout, 
cadence, distribution of bout 
length 
No Yes No 
Hiorth et al. 
(2015), 48 PD, 
741 
activPAL █ 
Sedentary 
behaviour/ 
standing/ 
walking 
Yes, but not formal in 
PD. Previous work in 
OA against other 
accelerometer 96 and 
video recordings in 
people with 
rheumatoid arthritis 
during simulation of 
ADL in the laboratory 
97 
Volume (e.g. total number of 
sedentary/standing/walking 
bouts), pattern (α), variability 
of sedentary bouts and 
number of strides per walking 
bout. 
Yes, against clinical scores Yes No 
Mactier et al. 
(2015), 111 PD, 
739 
activPAL █ Walking 
Yes, but not formal in 
PD. Previous work in 
OA against other 
accelerometer 96 and 
video recordings in 
people with 
rheumatoid arthritis 
during simulation of 
ADL in the laboratory 
97 
Volume (e.g. total number of 
walking bouts), pattern (α), 
variability of bouts, 
accumulation of stepping 
bouts 
No Yes No 
Rispens et al. 
(2015), 113 
OA, 1438 
Dynaport McRoberts █ 
Walking (at 
least 10s)  
Yes, previous work in 
OA 98 for walking 
volume parameters 
against videos, no for 
gait characteristics. 
Acceleration based outcomes: 
gait speed, speed variability, 
stride time, stride regularity, 
stride time variability, stride 
frequency, frequency domain 
measures (harmonic ratio, 
amplitude, slope and width of 
dominant frequency), etc. 
Yes, measures against self-
reported fall history 
No No 
van Schooten et 
al. (2015), 169 
OA, 837 
Dynaport McRoberts █ 
Walking (at 
least 10s), 
sitting, lying, 
and standing 
Yes, previous work in 
OA 98 for walking 
volume parameters 
against videos, no for 
Total duration of walking, 
sitting, 
standing, and lying per day, 
number of 
Yes, against falls history Yes No 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
gait characteristics. strides, number of walking 
bouts, duration of 
bouts, number of transitions. 
Gait characteristics: gait 
speed, stride frequency, stride 
length frequency domain 
measures (harmonic ratio, 
power at dominant 
frequency), etc. 
Kangas et al. 
(2015), 16 OA, 
5-15532 
CareTech Ab --█-- Fallsǂ 
Yes, fall event against 
care personnel’s 
reports and in 
previous work in OA 
during simulation of 
fall events in 
controlled conditions 
99 in OA  
Fall event with alarm 
generation 
No No 
Yes, based on 
alarm 
accuracy 
Freezing of Gait (FOG) 
Moore et al. 
(2013), 25 PD, 
NA43 
Xsens MTx  █ █ █ █ 
█ █ █ 
Turning/ 
walking 
(TUG)ǂ 
Yes, in the laboratory 
for FOG event against 
video recordings 
FOG event through 
acceleration derived 
frequency measures (power 
spectrum, etc.). 
No No No 
Tripoliti et al. 
(2013), 11 PD/5 
OA, NA44 
Body Sensor AGYRO, 
AGYRO links, ANCO 
S.A.█ █ █ █ █ █ 
Walking, FOG 
detectionǂ 
Yes, against video 
recordings and visual 
inspection during 
structured test 
(Opening door/ 
Straight 10m walking) 
sing different 
classification 
algorithms and cross-
validations 
FOG detection through 
entropy of WTCD signal 
No No No 
Weiss et al. 
(2015), 72 PD, 
345 
Dynaport McRoberts █ 
Walking (at 
least 60s) 
No 
Number of walking bouts, % 
of activity duration, total 
number of steps, median 
number of steps per bout, 
bout duration, cadence, stride 
regularity, frequency domain 
Yes, against clinical scores 
(FOG questionnaire) 
Yes No 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
measures (harmonic ratio, 
width of dominant 
frequency), etc. 
Gait 
Cancela et al. 
(2011), 10 PD, 
1 (not clear)58 
ALA-6g (PERFORM) 
--█-- █ █ █ █ 
Walking (on 
vs off 
medication) 
Yes, only for step 
frequency during 10m 
scripted protocol 
against visual 
examination 
Step frequency, stride length 
and speed, entropy, arm 
swing 
No 
Yes, only for 
entropy in 
previous work 100 
No 
Weiss et al. 
(2011), 22 
PD/17 OA 
(1PD/1CL at 
home), 357 
Mobi8 █ 
Walking 
(during 
scripted test in 
the lab and 
during 
simulation of 
ADL and free-
living) 
No 
Acceleration derived 
measures (time and frequency 
domains): stride time, stride 
time variability, amplitude, 
width, slope of dominant 
frequency, etc. 
Yes, against clinical scores Yes No 
Cancela et al. 
(2014), 11 PD, 
5-7 (8 hours per 
day)59 
ALA-6g (PERFORM) 
--█-- █ █ █ █ 
Walking 
Yes, only for step 
frequency, previous 
work (see Cancela 
2011) 
Step frequency, step velocity, 
stride length, entropy 
No 
Yes, only for 
entropy in 
previous work 100 
Yes, formal 
testing and 
also assessed 
in separate 
study 76 
Herman et al. 
(2014), 110 PD, 
361 
Dynaport McRoberts █ 
Walking (at 
least 60s) 
No 
Total number of activity 
bouts, total % of activity 
duration, total number of 
steps, mean activity bout 
duration, median number of 
steps per bout, cadence, stride 
regularity, amplitude of 
dominant frequency, width of 
dominant frequency, stride 
regularity, harmonic ratio, 
Phase Coordination Index. 
Yes, previous work 
Yes, previous 
work 
No. 
Weiss et al. 
(2015), 107 PD, 
360 
Dynaport McRoberts █ 
Walking (at 
least 60s) 
No 
Total % of activity duration, 
total number of steps, 
cadence, amplitude of 
dominant frequency, stride 
regularity, harmonic ratio, 
Yes, previous work 
Yes, previous 
work 
Yes, no 
formal testing, 
data loss 
reported 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
Phase Coordination Index. 
Del Din et al. 
(2016), 47 
PD/50 OA, 7 49 
Axivity AX3  █ 
Walking (at 
least 3 steps) 
No 
14 gait characteristics: mean 
step time, stance time, swing 
time, step length, step 
velocity, step time variability, 
stance time variability, swing 
time variability, step length 
variability, step velocity 
variability, step time 
asymmetry, stance time 
asymmetry, swing time 
asymmetry, step length 
asymmetry. 
Yes, gait characteristics 
validated against laboratory 
reference (previous work 53) 
Yes No 
Timed-up-and-go (TUG) 
Zampieri et al. 
(2011), 6 PD/8 
OA, 162 
Physilog  █ █ █ █ █ 
Walking/turni
ng/postural 
transitions ǂ 
Yes, in previous 
work101 
Cadence, stride velocity, 
stride length, peak arm 
velocity, turning velocity 
No Yes No 
Smith et al. 
(2016), 12 OA, 
563 
SHIMMER █  █ 
Walking/turni
ng ǂ 
No 
Time to complete test, 
cadence, gait characteristics 
(step time, stride time, stride 
length, stride velocity, etc.), 
turning magnitude, etc. 
No No No 
Turning 
El-Gohary et al. 
(2013), 12 
PD/18 OA, 7*65 
Opal(ADPM) --█-- in 
the lab / Opal(ADPM) 
--█-- █ █ at home 
Turning/ 
walking (at 
least 10s) 
Yes, in the lab against 
motion analysis 
system and video 
recordings 
Number of turns, peak 
velocity, mean velocity, 
duration of turn 
No Yes No 
Mancini et al. 
(2015), 13 PD/8 
OA, 7*64 
Opal(ADPM) --█-- █ 
█ 
Turning/ 
walking (at 
least 10s) 
Yes, in the lab 
(previous work, see 
El-Gohary 2013) 
Number of turns/hour, turn 
angle, turn duration, number 
of steps/turn, turn mean 
velocity and coefficient of 
variation of these measures. 
Yes Yes 
Yes, no 
formal testing, 
report of 
‘ease’ of use. 
Ambulatory activity and sedentary behaviour 
Chastin et al. 
(2010), 17 
PD/17 OA, 771 
activPAL █ 
Sedentary 
behaviour 
Yes, but not formal in 
PD. Previous work in 
OA against other 
Volume of sedentary bouts, 
pattern (α), pattern of 
accumulation of bouts (GINI 
No Yes No 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
accelerometer 96 and 
video recordings in 
people with 
rheumatoid arthritis 
during simulation of 
ADL in the laboratory 
97  
index) 
Dontje et al. 
(2013), 467 PD, 
1470 
TracmorD, Philips/ 
--█-- or --█-- or █ 
Physical 
Activity/Seden
tary behaviour 
Yes, against doubly 
labeled water 
technique (correlation) 
in adults but not in PD 
102 
Energy expenditure, time 
spent in activities, distribution 
of activities, etc. 
Yes No No 
Benka Wallen 
et al. (2015), 95 
PD, 7103 
ActiGraph GT3X+  --
█-- 
Physical 
Activity/Seden
tary 
behaviour/ 
Steps (60s 
epochs) 
Yes, in young adults 
under controlled 
conditions by visual 
observation but not in 
PD 104 
Volume (magnitude vector of 
acceleration) and time spent 
in physical activities, steps 
per day, etc.   
No No No 
Lim et al. 
(2010), 153 PD, 
174 
Vitaport3, TEMEC 
Instruments BV  █ █ 
█ █ █ 
Sitting, 
standing, 
walking 
Yes in PD against 
video (under 
controlled conditions), 
previous work 105 
% of time spent on dynamic, 
static, sitting, standing or 
walking activities, number of 
walking bouts > 5s and > 10s 
No No No 
Cavanaugh et 
al. (2012), 33 
PD, 772 
StepWatch 3 Step 
Activity Monitor 
(SAM) █ 
Walking 
(average every 
60s) 
Yes, for stride count 
in PD against 
instrumented walkway 
in the lab, previous 
work  106 
Total number of steps, 
maximum output for steps, 
number of minutes with > 100 
steps, number and duration of 
walking bouts, peak activity 
index, % of day spent inactive 
No No 
Yes, not 
formal testing, 
reasons for 
data loss and 
attrition in 
sensor 
acceptability 
after 1 year 
with decrease 
in participant 
use reported 
Rochester et al. 
(2012), 17 PD, 
768 
activPAL █ Walking 
Yes, but not formal in 
PD. Previous work in 
OA against other 
accelerometer 96 and 
video recordings in 
Volume of walking bouts, 
pattern of accumulation of 
bouts (GINI index) and 
diversity of bouts, distribution 
and variability of bouts (S2)  
Yes No No 
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Study (Year), 
N, Length of 
recording 
WTCD and 
placement 
 
Clinical 
feature/ 
Activity 
Accurate detection 
of clinical feature: 
Method of 
appraisal† 
Measures  Criterion Validity† 
Discriminative 
Validity† 
Utility 
people with 
rheumatoid arthritis 
during simulation of 
ADL in the laboratory 
97 
Lord et al. 
(2013), 89 
PD/97 OA, 766 
activPAL █ Walking 
Yes, but not formal in 
PD. Previous work in 
OA against other 
accelerometer 96 and 
video recordings in 
people with 
rheumatoid arthritis 
during simulation of 
ADL in the laboratory 
97 
Volume of walking bouts, 
pattern (α), time spent 
walking in short-medium or 
long bouts, frequency and 
variability of bouts (S2) 
Yes Yes No 
Cavanaugh et 
al. (2015), 17 
PD, 773 
StepWatch 3 Step 
Activity Monitor 
(SAM) █ 
Walking 
(average every 
60s) 
Yes, for stride count 
in PD against 
instrumented walkway 
in the lab, previous 
work (see Cavanaugh 
2012) 
Mean daily steps, maximum 
output for steps, Moderate 
intensity minutes  (number of 
minutes with > 100 steps) 
Yes No 
Yes, not 
formal testing,  
reasons for 
data loss and 
attrition in 
sensor 
acceptability 
after 2 years 
with decrease 
in participant 
use reported 
ADL = Activities of Daily Living; Alpha = α; Lab = Laboratory; Length of recording= number of weeks/days/minutes of recording; MBRS = Modified Bradykinesia Rating Scale; min = 
miutes; N = number of participants; OA = Older Adults; PD = Parkinson’s disease; RMS = Root Mean Square; UPDRS = Unified Parkinson's Disease Rating Scale; % = Percentage; *Night 
excluded; ǂ = scripted protocol/supervised conditions used.  
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Table 2: Practical solutions and broad recommendations for WTCD-related research challenges. 
 
Recommendation Practical solutions  
Adopt standardised definition of 
activity/clinical feature  
 
 
 Justify definition of activity/clinical feature with respect to 
earlier work & clinical expertise. 
 
 Adopt interdisciplinary collaboration for optimal process, 
choice of equipment, protocol, data processing and outcomes 
adhering to research question(s). 
 
Select equipment depending on 
research/clinical question; evaluate trade-
off between information needed & 
equipment available. 
 
 
 Consider optimal technical specifications (e.g. sampling 
frequency, type of data collected; battery life) for outcome 
measures.  
 
 Use WTCD with established utility, acceptability and cost-
effectiveness, otherwise plan to include tests of utility and 
acceptability as part of the study. 
 
 Ensure transparency of all aspects of technology used 
(specifications, data collection, data pre-processing). 
 
Use standardised protocols & validation 
procedures for algorithms for 
comparability & reproducibility across 
studies (e.g. accurate detection of 
activity/clinical feature, criterion & 
discriminative validity). 
 
 
 Justify use of standardised protocol & methods to define 
activities/clinical features. 
 
 Use algorithms previously validated four the current 
application or provide validation results for novel algorithms. 
 
 Use appropriate gold standards (e.g. video recording) to 
validate outcomes/metrics in free-living conditions, not 
limiting validation to scripted protocols or controlled 
conditions. 
 
 Account for influence of context and disease severity on 
algorithm performance. 
 
 If proprietary software is used ensure transparency of 
manufacturer algorithms or report published validated 
algorithm. 
 
Achieve consensus for summary 
outcomes for comparability across 
studies.  
 
 
 Use WTCD-based outcomes validated in free-living; or 
provide validation results in the current study using semi-
structured activities. 
 
 Describe (if any) dependence of chosen summary outcomes & 
on chosen data processing/algorithm. 
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Figures 
Figure 1: 
Use of wearable technology and connected devices (WTCD) (adapted with permission from previous 
work) 47 A)  macro level quantification of activities over an extended period of time (volume, patterns 
and variability); (B) bouts of activities (e.g. lying (sleeping), walking, sitting); (C-H) micro level 
quantification from specific events: C) and D) postural transitions, E) shuffling, F) gait, G) turning, H) 
freezing of gait (FOG) and fall. 
 
Figure 2: 
Examples of linear and non-linear approaches to activity data analysis: volume and pattern metrics for 
two subjects (Subject 1 and 2) (published with permission) 68. 
A1 and A2 - Patterns of activity indicating bouts of sedentary, standing and walking at different 
stepping rates (cadences). 
B1 and B2 - Volume Metrics: total walking time for the two subjects is equal but made up of walking 
bouts at different cadences. 
C - Pattern Metrics: (i) and (ii) distribution of walking bouts for these two subjects with equal mean 
(M) and different dispersion (S2). C (iii) Accumulation pattern of walking time for subject 1 and 2; 
subject 2 tends to accumulate walking time with predominantly longer periods. 
 
Figure 3:  
Challenges/limitations of free-living measurement using examples from gait in free-living collected 
with a single accelerometer-based WTCD. Data (unpublished) from the Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation-GAIT (ICICLE-GAIT) study 107. 
 
Panel (1) – Definition of feature of interest (e.g. walking):   
A) Impact of “selected” definition of walking on data processing: different threshold of walking 
bout length and (ghost) maximum resting period (MRP) between consecutive walking bouts 
can be utilised.  
Examples: (i): use of walking bout threshold of 60s and no MRP (MRP = 0s) (only bouts 
longer than 60 s will be considered); (ii): use of walking bout threshold of 3 steps and no 
MRP (MRP = 0s); (iii) use of walking bout threshold of 3 steps and MRP = 5s. 
B) Impact of choice in A) on macro outcomes (e.g. number of bouts considered, total number of 
steps reported for people with Parkinson’s disease (PD) and controls (CL)). For example 
using definition (i) only a small percentage of all the walking bouts will be considered (bouts 
> 60s only) and therefore fewer steps will be reported if compared to results of using 
definition (ii). 
C) Impact of choice in A) on micro gait characteristics (e.g. reported step velocity may vary 
across studies due to choice of definition ((i), (ii) or (iii)). 
 
Panel (2) – Influence of free-living protocol on data: 
Walking speed changes with respect to the environment, task, and disease severity which 
influences the accelerometer raw signal (D) impacting on algorithm performance and 
evaluation of outcomes (E). 
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